Vernieri Claudio, Casola Stefano, Foiani Marco, Pietrantonio Filippo, de Braud Filippo, Longo Valter
Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Fondazione Istituto FIRC di Oncologia Molecolare (IFOM), Milan, Italy.
Cancer Discov. 2016 Dec;6(12):1315-1333. doi: 10.1158/2159-8290.CD-16-0615. Epub 2016 Nov 21.
Most tumors display oncogene-driven reprogramming of several metabolic pathways, which are crucial to sustain their growth and proliferation. In recent years, both dietary and pharmacologic approaches that target deregulated tumor metabolism are beginning to be considered for clinical applications. Dietary interventions exploit the ability of nutrient-restricted conditions to exert broad biological effects, protecting normal cells, organs, and systems, while sensitizing a wide variety of cancer cells to cytotoxic therapies. On the other hand, drugs targeting enzymes or metabolites of crucial metabolic pathways can be highly specific and effective, but must be matched with a responsive tumor, which might rapidly adapt. In this review, we illustrate how dietary and pharmacologic therapies differ in their effect on tumor growth, proliferation, and metabolism and discuss the available preclinical and clinical evidence in favor of or against each of them. We also indicate, when appropriate, how to optimize future investigations on metabolic therapies on the basis of tumor- and patient-related characteristics.
To our knowledge, this is the first review article that comprehensively analyzes the preclinical and preliminary clinical experimental foundations of both dietary and pharmacologic metabolic interventions in cancer therapy. Among several promising therapies, we propose treatment personalization on the basis of tumor genetics, tumor metabolism, and patient systemic metabolism.Cancer Discov; 6(12); 1315-33. ©2016 AACR.
大多数肿瘤表现出由癌基因驱动的多种代谢途径重编程,这些途径对于维持肿瘤的生长和增殖至关重要。近年来,针对失调的肿瘤代谢的饮食和药物治疗方法开始被考虑用于临床应用。饮食干预利用营养限制条件发挥广泛生物学效应的能力,保护正常细胞、器官和系统,同时使多种癌细胞对细胞毒性疗法敏感。另一方面,针对关键代谢途径的酶或代谢物的药物可能具有高度特异性和有效性,但必须与可能迅速适应的反应性肿瘤相匹配。在本综述中,我们阐述了饮食和药物疗法在对肿瘤生长、增殖和代谢的影响方面有何不同,并讨论了支持或反对它们的现有临床前和临床证据。我们还在适当的时候指出,如何根据肿瘤和患者相关特征优化未来关于代谢疗法的研究。
据我们所知,这是第一篇全面分析癌症治疗中饮食和药物代谢干预的临床前和初步临床实验基础的综述文章。在几种有前景的疗法中,我们建议根据肿瘤遗传学、肿瘤代谢和患者全身代谢进行治疗个性化。《癌症发现》;6(12);1315 - 33。©2016美国癌症研究协会。